Task order 2: next anti-CFH AB (CBAB1) tissue cross-reactivity study of a human antibody
Ended Awarded Last action
- Contract number
- HHSN26100002
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $212,247
Award facts
- Opportunity
-
- N02CM4700142 Solicitation number
- Preclinical toxicology of drugs developed for cancer patients Award Notice · Posted Apr 4, 2014
- Contract value 100% obligated
- $212,246.94 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$5,707 | |
| Original award | $217,954 |
About this award
The National Cancer Institute issued a delivery order to Sri International on May 10, 2018, with a ceiling value of $212,246.94, under the Toxicology of Drugs Developed for Cancer Patients IDIQ for a tissue cross-reactivity study of a human antibody in support of next-generation anti-CFH AB (CBAB1) development.
Place of performance is Menlo Park, CA. The order is priced on a cost-plus-fixed-fee basis with an ultimate completion date of March 31, 2019. Sri International, a non-profit research and development organization, performs research services across biomedical sciences, defense technologies, and other domains for federal agencies.
Quick answers
Who was awarded contract HHSN26100002?
HHSN26100002 was awarded to Sri International by National Cancer Institute (National Institutes of Health) on May 10, 2018.
How much is contract HHSN26100002 worth?
The government has obligated $212,247 on HHSN26100002.
Is contract HHSN26100002 an order under another contract?
Yes. HHSN26100002 is a delivery order under HHSN261201600017I, an indefinite delivery contract, on Toxicology of Drugs Developed for Cancer Patients.
Was contract HHSN26100002 competed?
The extent of competition for HHSN26100002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award